Mirion Technologies, Inc.

Mirion Technologies, Inc. (MIR) Market Cap

Mirion Technologies, Inc. has a market capitalization of .

No quote data available.

CEO: Thomas D. Logan

Sector: Industrials

Industry: Industrial - Machinery

IPO Date: 2020-08-20

Website: https://www.mirion.com

Mirion Technologies, Inc. (MIR) - Company Information

Market Cap: -|Sector: Industrials

Company Profile

Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, and Japan. It operates through two segments, Medical and Industrial. The medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Industrial segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.

Analyst Sentiment

83%
Strong Buy

From 10 Active Polls

1Y Forecast: $28.25

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$27

Median

$29

High Bound

$29

Average

$28

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$28.25
▲ +65.40% Upside
Low Target
$27.00
58% Risk
Median Target
$28.50
67% Mid
High Target
$29.00
70% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 MIRION TECHNOLOGIES INC CLASS A (MIR) — Investment Overview

🧩 Business Model Overview

Mirion Technologies supplies radiation detection and measurement solutions used to monitor, verify, and manage exposure risk across nuclear power, defense & homeland security, industrial radiological applications, and healthcare/medical workflows. The value chain spans (1) engineering and manufacturing of detectors and measurement systems, (2) integration into customer environments and workflows, and (3) lifecycle support such as calibration, servicing, dosimetry management, and compliance-related measurement services.

A key feature of the model is that once measurement equipment is qualified and integrated, customers rely on Mirion’s instruments and services to maintain regulatory compliance and operational safety—creating structural customer stickiness.

💰 Revenue Streams & Monetisation Model

Mirion monetizes through a blend of product and service revenue. Revenue is typically driven by:

  • System and equipment sales (detectors, monitoring systems, and measurement hardware) tied to nuclear, security, and industrial project activity.
  • Recurring or repeatable services including calibration, servicing, and related lifecycle support for in-place installations.
  • Dosimetry and measurement services where customers outsource exposure monitoring and data management, supporting ongoing compliance needs rather than one-time purchases.

Margin structure generally reflects that lifecycle services and measurement-related offerings tend to be more repeatable than new system installs, while the company’s measurement hardware benefits from scale in component sourcing and manufacturing know-how. Over time, the mix shift toward service and dosimetry-like recurring activities can support more stable gross margin and cash conversion than purely transactional equipment sales.

🧠 Competitive Advantages & Market Positioning

Mirion’s durable advantages center on high switching costs and regulatory/qualification barriers rather than consumer-style brand strength.

  • Switching Costs (Installed Base & Qualification): Radiation measurement is safety-critical. Customers often require specific performance specifications, calibration regimes, and validation within regulated environments. Re-qualifying alternate systems can be costly in both time and compliance risk, which increases customer retention.
  • Intangible Assets (Measurement Expertise & Technology): Proprietary detector technologies, signal processing, and engineering processes build cumulative know-how. Competitors can offer substitutable hardware, but matching performance and integration outcomes across customer sites is non-trivial.
  • Regulatory Moats (Compliance-Critical Workflows): Demand is anchored in meeting regulatory obligations (radiation safety, monitoring, and verification). This tends to favor vendors with proven track records, documentation, and service capability.

Competitive benchmarking:

  • Teledyne Technologies (radiation detection and related instrumentation offerings) competes for measurement solutions across government and industrial end markets.
  • Smiths Detection focuses heavily on detection and inspection equipment for security and checkpoint applications.
  • Thermo Fisher Scientific competes across elements of radiation measurement, dosimetry, and scientific/medical adjacencies depending on application.

Positioning contrast: Mirion’s emphasis spans civilian nuclear operations (including decommissioning and environmental monitoring), security/home-land applications, industrial radiological measurement, and dosimetry-related services, whereas some rivals skew more toward security-centric detection platforms (e.g., checkpoint/inspection) or broader scientific instrument portfolios. Mirion’s differentiation is the combination of measurement systems with ongoing lifecycle support and compliance workflows, which can be harder to replicate end-to-end.

🚀 Multi-Year Growth Drivers

A durable outlook rests on secular demand for radiation safety and verification. Over a 5–10 year horizon, addressable demand is supported by:

  • Nuclear lifecycle intensity: Extended operation of existing nuclear fleets, plus decommissioning and waste management, drives continuous needs for monitoring, verification, and radiation safety instrumentation.
  • Regulatory and compliance requirements: Governments and regulators require robust radiation monitoring and exposure tracking, favoring vendors that can provide measurement performance and sustained support.
  • Security and threat-detection modernization: Continued procurement and upgrades for radiation detection systems and improved sensing capabilities sustain program-based demand.
  • Industrial adoption in radiological processes: Growth in inspection and radiological applications expands the need for reliable measurement systems and safety oversight.
  • Healthcare/medical workflow demand: Where applicable, increased utilization of radiation-based therapies and diagnostics supports demand for measurement and quality assurance solutions that improve safety and workflow reliability.

Collectively, these trends support both (1) project-driven instrument demand and (2) ongoing service revenue anchored to an installed base—an important mix for multi-year earnings resilience.

⚠ Risk Factors to Monitor

  • Government and program budgeting risk: Security and defense-related demand can be influenced by procurement cycles and changes in government priorities.
  • Customer qualification and integration lead-time: Safety-critical systems can require long validation cycles; procurement delays can affect timing of revenue recognition.
  • Technology and performance risk: Competitors may introduce incremental improvements in detectors or analytics. Mirion must maintain performance credibility across regulated use cases.
  • Capital intensity and working-capital swings: Large system builds and project execution can create inventory and receivables volatility, impacting cash flow.
  • Concentration and end-market exposure: A portion of demand may track nuclear build/decommission schedules and regulated compliance budgets, which can vary by region and policy.
  • Regulatory and liability considerations: Radiation measurement is safety-critical; changes in standards, warranty/service obligations, or incident-related scrutiny can affect costs.

📊 Valuation & Market View

Markets typically value Mirion as an industrial technology and measurement/services business using a combination of:

  • EV/EBITDA and EV/Revenue to capture cyclicality versus service-like stability.
  • Forward margin and cash-flow expectations given the importance of mix (systems versus services/dosimetry-like recurring work) and operational execution.

Key valuation drivers include: sustainable service revenue contribution, evidence of durable customer retention tied to qualification and installed base, execution against project schedules, and cash conversion quality (working-capital management and lifecycle services scalability).

🔍 Investment Takeaway

Mirion’s investment case rests on measurement criticality and compliance-driven switching costs. The company is positioned to benefit from long-duration demand in nuclear lifecycle activities, radiation safety and monitoring requirements, and security modernization. The moat is less about a single product advantage and more about sustaining trust and performance across qualified installations through technology depth, lifecycle support, and regulatory fit.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"MIR reported Q1 2026 Revenue of $257.6M (QoQ: -7.2%; YoY: +27.5%) with EPS of -$0.01 and Net Income of -$3.4M (QoQ: vs +$17.3M in Q4; YoY: vs +$0.3M in Q1’25). Margins contracted sharply: gross margin was 46.2% (slightly down vs ~48.8% in Q4 and ~47.6% in Q1’25), while operating margin fell to 1.4% from 9.2% in Q4. Profitability weakened materially across the quarter, with operating income of $3.7M reversing from strong profitability in Q4. Cash flow remains positive: operating cash flow was $18.9M, and free cash flow was $9.4M, but the quarter did not translate earnings losses into meaningful cash cushion (net income stayed negative). On the balance sheet, leverage appears heavier vs the prior quarter: total debt increased materially to $790.4M from $1.261B is a data inconsistency to reconcile, but net debt is still high at $392.5M. Equity is substantial at $1.89B, but retained earnings remain deeply negative ($-516.1M), limiting balance-sheet confidence. Total shareholder returns look supportive given the stock’s +42.5% 1-year change, with no dividend yield. Price-to-target context appears modestly upside to consensus $28.5 vs current ~$19.72."

Revenue Growth

Positive

Revenue rose YoY to $257.6M (+27.5% vs Q1’25) but declined QoQ (-7.2% vs Q4’25). Trend is growth year-over-year but not stable sequentially.

Profitability

Neutral

Net income swung to a loss of -$3.4M (QoQ: from +$17.3M; YoY: from +$0.3M). Operating margin fell to 1.4% from 9.2% in Q4, indicating contracting profitability.

Cash Flow Quality

Fair

Operating cash flow remained positive at $18.9M and free cash flow was $9.4M, but this was not enough to offset the earnings deterioration. No dividends and no buyback/repurchase signal in the cash flow beyond -$20.1M repurchases.

Leverage & Balance Sheet

Fair

Equity is strong at $1.89B (QoQ slightly up), and liquidity is high (cash $397.9M; current ratio ~3.19). However, retained earnings are deeply negative (-$516.1M) and net debt remains elevated ($392.5M).

Shareholder Returns

Good

Strong market momentum: +42.49% over 1 year. No dividend yield (0%), but cash flow shows $20.1M of share repurchases in Q1.

Analyst Sentiment & Valuation

Neutral

Consensus target $28.5 vs current price ~$19.72 implies upside of ~44%. Valuation metrics are distorted by negative earnings (P/E not meaningful).

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Mirion delivered a strong Q1 2026 with orders accelerating sharply: +19% excluding M&A to $241M and +42% including Paragon/CertRec to $288M, lifting backlog to $1.1B (+19% ex-M&A, +38% incl. M&A). Revenue rose 28% to $258M (3% organic), and adjusted EBITDA grew to $54M (+16%), but margins contracted due to margin-dilutive M&A, prior-year one-timers, and sensing-related mix shifts. The investment case hinges on nuclear installed-base reinvestment and SMR momentum: SMR revenue is 2% of revenue today, targeted to exceed 3% by year end, with $50M large opportunity orders secured in Q1 and an additional $35M SMR-related award in April. Medical also improved—RTQA benefited from a Varian-linked radiation-tolerant camera order and management maintained double-digit organic nuclear medicine growth guidance. Outlook remains intact: Q2 orders expected +15% to +20% sequential; organic revenue low single digits; EBITDA margins flat; with Paragon ~25% full-year revenue growth and low-twenties margins.

AI IconGrowth Catalysts

  • Nuclear and Safety: installed-base power-related orders from existing U.S. fleet (capacity factors ~low 90%) and SMR momentum (large SMR order partials booked; $15M in Q1 plus $35M awarded in April).
  • Nuclear and Safety: large opportunity pipeline conversion—$50M secured in Q1 and $35M SMR-related orders awarded in April.
  • Paragon/CerRec integration driving incremental wins: Paragon revenue up 45% in Q1, expanding operating leverage and margin.
  • Medical RTQA: radiation-tolerant camera order tied to the Varian partnership; backlog support for next three years.
  • Nuclear medicine: guidance maintained for double-digit organic revenue growth in 2026 (second consecutive year).
  • Dosimetry services: continued GDP-plus through-cycle growth; digital dosimeters creating nuclear power cross-sell opportunities.

Business Development

  • Paragon acquisition: additional synergy and integrated nuclear sales execution; Paragon CEO referenced (Doug VanTassel).
  • CertRec acquisition: regulatory/workforce software layer for labor-constrained environments and plant compliance workflows.
  • Varian partnership: radiation-tolerant camera order booked in U.S. RTQA tied to Varian.
  • EDF/Framatome strategic alliance referenced for expected participation in France projects (Penly, Bugey, Gravelines).
  • DOE Uprise Initiative referenced as a driver of nuclear capacity reinvestment (U.S. existing capacity boost targets).
  • Customer spending context and existing year-end customers referenced: Duke Energy and NextEra.

AI IconFinancial Highlights

  • Orders: +19% in Q1 to $241M excluding M&A; +42% including M&A growth from Paragon and CertRec to $288M.
  • Backlog: $1.1B total; up 19% excluding M&A and 38% including M&A.
  • Revenue: $258M total, +28% YoY; organic revenue +3% (in line with expectations).
  • Adjusted EBITDA: $54M, +16% YoY; EBITDA margin contracted due to margin-dilutive M&A, Q1 prior-year one-timers, and mix shift (legacy Nuclear & Safety, mainly sensing).
  • Adjusted EPS: 10¢ per share; company noted 2026 adjusted EPS methodology now includes stock-based comp (prior year would have been 8¢ using similar methodology).
  • Cash flow: $11M adjusted free cash flow (Q1 historically lightest; working capital timing headwind).
  • Segment performance: Nuclear & Safety revenue $186M (+39%); organic +2.6% (better than Feb expectation of flat). Medical revenue $72M (+5%); organic ~4%.
  • Nuclear & Safety: adjusted EBITDA grew nearly $8M (+19%) to $47M; margin contraction half M&A, half mix/one-timers and sensing-related shifts.
  • SMR revenue mix: SMR is 2% of total revenue in Q1, expected to exceed 3% by year end.

AI IconCapital Funding

  • Share repurchase: utilized ~$16M of the $100M share repurchase program to buy back ~700k shares in Q1.
  • Adjusted free cash flow: $11M generated in the quarter; management stated Q1 is a trough for cash generation with improved working capital/project cash flow line-of-sight in subsequent quarters.

AI IconStrategy & Ops

  • Integration: Paragon and CertRec integration cadence progressing; identified additional synergy opportunities and prioritized joint customer engagements across strategic accounts.
  • Commercial flywheel: customers eager to realize benefits of a combined Mirion/Paragon/CertRec entity; resulting in incremental order wins.
  • Large opportunity pipeline: 5 large opportunity orders referenced; Paragon-related orders constitute two of the five; some RTQA and battery orders were not in year-end pipeline, indicating dynamic pipeline flow.
  • China/tariff execution timing: management highlighted prior-year shipment into China before tariffs; this created a Q2 headwind.

AI IconMarket Outlook

  • Q2 order growth: sequential Q1 to Q2 expected +15% to +20% in orders.
  • Q2 organic revenue growth: consolidated low single digits; also expected low single digits in each operating segment.
  • Q2 EBITDA margins: consolidated adjusted EBITDA margins relatively flat vs Q2 2025.
  • Nuclear & Safety: margins relatively flat despite Paragon margin-dilutive impacts; excluding Paragon, Nuclear & Safety adjusted EBITDA margins expected to expand.
  • Paragon: Q2 revenue expected slightly lower than Q1 but still double-digit YoY; maintained full-year expectations of ~25% revenue growth and low-twenties EBITDA margins.
  • Medical: margin expected to expand slightly; management cites lapping a difficult prior-year Q2 comp (prior-year Medical Q2 margins expanded almost 300 bps).
  • Full-year guidance: management stated nothing changed from February disclosures except a small adjusted EPS adjustment for a one-time CEO retention grant of performance-vesting stock options.

AI IconRisks & Headwinds

  • Margin pressure in Q1: margin-dilutive M&A, prior-year one-timers, and sensing-related mix shift in legacy Nuclear & Safety.
  • Q2 headwind: shipments into China before tariffs went into effect in 2025; this impacts Q2 comparables.
  • Medical variability: Asian market challenges still under watch; U.S. market monitored (no guidance change, but confidence improving).
  • Cash flow lumpiness: Q1 had fewer project inflows than a year ago; working capital used most cash in the quarter.
  • Defense end market is lumpy and can vary quarter to quarter (management noted picked up activity but variability remains).

Q&A: Analyst Interest

  • Nuclear buildout acceleration drivers: Management emphasized installed-base psychology shift as capacity-factor constraints tighten (U.S. low-90% capacity factors; global ~82%). They linked reinvestment to extended operating life (60 to 80, but moving toward 100) driving I&C, radiation protection digitalization, and reactor protection upgrades.
  • Medical sustainability vs bounce: Management said Medical remains within full-year guidance without changes, but expressed improved confidence versus three months ago. They attributed strength to software/services performance and the Varian-linked radiation-tolerant camera order bolstering backlog, while monitoring Asia and the U.S. for continued green shoots.
  • Backlog conversion visibility and 2027 outlook: Management stated confidence would have changed the EBITDA/revenue guide if different; they expect 2026 to be back-end loaded. They avoided 2027 numeric guidance, but argued backlog growth should recur in Q2, indicating constructive visibility beyond 2026.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the MIR Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Mirion Technologies, Inc. (MIR) Financial Profile